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 The authors investigate whether or not companies within the pharmaceutical industry still 
have a hard time effectively designing and following an electronic validation system.  With 
increased data integrity issues from electronic systems, the FDA introduced 21 CFR Part 11 in 
1997 to allow for the use of electronic signature and records for processes within the 
pharmaceutical industry.  This regulation also required that the computer and electronic systems 
be available for audits and inspections by the FDA.  In order to comply with 21 CFR Part 11 and 
adapt to new technology, companies must have an electronic validation system.  The electronic 
validation system requires that the company provides documented proof that regulatory 
standards are met and electronic procedures have been tested and can assure quality results.  A 
review of current literature examines how the industry utilized electronic validation after the 
introduction of 21 CFR Part 11.  Finally, a case study is presented to see how a current company 
maintains its electronic validation system.  The objective of this study is to look into a current 
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I.  Introduction 
    Despite the fact that nearly twenty years have passed since the FDA introduced key 
regulations regarding electronic validation, the pharmaceutical industry still struggles to meet 
compliance regulations and adapt to new technology while trying to continue to deliver products 
safely and in a timely manner.  The electronic validation process makes sure that a company’s 
computer processes produce quality results (Stause, 2009).  The validation process within the 
pharmaceutical industry requires that companies have documented proof that quality and 
regulatory procedures are being followed during every step of the manufacturing and distribution 
process (Peters & Ferrence, 2013).  One of the most important FDA regulations that companies 
have to be in compliance with is 21 CFR (Code of Federal Regulations) Part 11. 
In 1997, FDA introduced 21 CFR Part 11 for companies that chose to maintain and 
submit records electronically to FDA.  21 CFR Part 11 lays down the regulations for electronic 
signatures and electronic records to be considered reliable and trustworthy “and essentially 
equivalent to paper records and handwritten signatures” (“Meeting the FDA’s Requirements”, 
n.d.).  The purpose of 21 CFR Part 11 was to allow companies to take advantage of using 
electronic technology while consumer safety was upheld based on standards set forth by FDA 
(“FDA to Conduct Inspections,” 2010).  The FDA introduced 21 CFR Part 11 out of concern for 
consumer safety regarding electronic and computer processes that were emerging in the mid to 
late 1990s.  During the 1990s, FDA discovered that software failures and defects accounted for 
7.7% of medical device recalls with a majority of these defects occurring when changes were 
made to software after initial installation and distribution (Bendale et al., 2011).  As a result of 
their findings, the FDA dictated that validation for all processes from buildings and equipment to 
computer systems would be required to show that quality standards can be met.  For electronic 
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validation, all computer software and hardware required documentation to prove that processes 
meet standards, that proper testing of software was done, and verification through inspection and 
review had been conducted.  In addition to the use of electronic signature and records, an 
important part of 21 CFR Part 11 also dictates that computer hardware and software system, 
controls, and documentation be maintained and made available for FDA inspection (“Part 11 – 
Electronic Records; Electronic Signatures,” 2015).  This piece of the regulation underlines the 
need of a validation system. 
II.  Electronic System Validation 
In his article, Yin (2010) mentions that the FDA believed that the introduction of 21 CFR 
Part 11 would encourage companies to adapt to new technology through deployment in different 
operations—from research, manufacturing, and marketing to the validation process.  However, 
some barriers were experienced while attempting to use this new technology.  The main premise 
of 21 CFR Part 11 assumed that the industry had the right software infrastructure, capabilities, 
and validation system to comply with regulations.  Yin believes that when the FDA first 
introduced 21 CFR Part 11, they were not aware that there was a gap between how the industry 
perceived the utilization of available technology and how regulatory concerns would actually be 
addressed.  While regulatory demands to adopt electronic signature processes were expected by 
the FDA, many areas in the industry did not have a full understanding of this technology and 
how to use it within the validation process. They also did not have great knowledge on the 
software systems available. 
To take advantage of emerging technology, companies would have to have an effective 
electronic validation system in place that could accommodate and adequately document 
changing technology.  The introduction of 21 CFR Part 11 presented companies with the 
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opportunity to update their business strategy.  Companies could create business strategies to 
create or improve upon processes that would take advantage of new technology and also make 
sure that their documentation and validation system would keep them compliant.  The industry 
had to be educated on how to make use of technological advances that could help improve 
processes and product quality while enabling them to respond to consumer expectations and 
demands (Budihandojo et al., 2007).   
Yin (2010) mentions how many pharmaceutical companies did not consider validation of 
their electronic system as a high priority or even as part of their organizational culture. While 
pharmaceutical companies were used to validating their manufacturing steps, they did not worry 
too much about their electronic system and usually had outside vendors to maintain their 
electronic systems.  The FDA assumed that companies would validate their electronic systems 
and processes similar to the way that they validated their manufacturing processes.  This 
misunderstanding of the need for electronic system validation and a focus on specific parts of the 
21 CFR Part 11 regarding just electronic records and signatures resulted in some companies 
spending millions of dollars trying to meet regulatory demands without establishing a reliable 
electronic validation system that produced adequate documentation or had the ability to adapt 
and accommodate new technology.  For instance, Procter & Gamble established Electronic 
Records Electronic Signature (ERES) teams to make sure different regulations were being met 
by each department (Siconolfi, 2005).  While the approach did address regulatory concerns, it 
did not produce a new and more efficient electronic validation system for the company.  Instead 
the teams proceeded to focus on specific processes that used electronic signatures.  While many 
companies focused on ways to utilize current technology, a new approach was needed within 
pharmaceutical companies to ensure that their validation system would help to keep them in 
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compliance and able to adapt to technological advances and changes from year-to-year.  The 
validation of electronic systems had to be prioritized and considered an important part of the 
culture of the company (Richman, 2005). 
II.A.  Electronic System Validation Expectations 
Some companies have started to realize the need to focus on the validation system rather 
than just regulatory requirements.  One of the main parts of the validation system is the 
documentation of procedures and system components (Ferris, 2000).  A good validation system 
consists of adequate documentation to ensure that if there is a change in technology or regulatory 
procedures, the right information can be tracked down and adjustments can be 
made.  Additionally, this process ensures that records and information do not get lost when 
moving from an old system into a new system.   
A challenge that companies have faced over the past two decades is that not all processes 
have become totally paperless.  Some companies use hybrid systems that include both paper 
records and electronic records.  Both processes have to be validated with documentation and 
security measures to ensure data integrity.  In 2005, Able Laboratories ran into major compliance 
issues when a major inconsistency appeared between their paper records and their electronic 
records resulting in massive FDA enforcement measures (McCulloch, Woodson, and Long, 
2014).  Able Laboratories had to stop all production and recall its entire product line.  The FDA 
found specific members of the quality assurance and quality control staff to have violated good 
manufacturing practices (GMPs) with accusations of data manipulation.  Violations of standard 
operating procedures (SOPs) was also evident due to the lack of record keeping as well as 
allowing for continued distribution of the drug products after bad laboratory results.  Able 
Laboratories ended up filing for bankruptcy and going out of business (Taylor, 2012). 
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        Data integrity is essential for pharmaceutical companies as the FDA and other regulatory 
agencies are concerned about the whole product life cycle.  McCulloch, Woodson, and Long 
(2014) discuss how research laboratories need to consider the different parts of their processes 
that generate data that will be under FDA scrutiny.  Equipment and facilities need to not only 
have gone through qualification processes and testing, but these activities should be well 
documented either in logbooks or an electronic system.  Other record keeping could also include 
the life cycle of product samples, testing, and disposal.  Records need to include a great amount 
of detail on the origination of all raw materials, lot numbers, and equipment used.  The company 
should establish processes and SOPs that are consistently followed during testing and studies.  
These protocols should generate valid data and also have procedures on how to handle output 
that deviates from the norm.  All data needs to be recorded in a timely manner either 
electronically or in designated logs and notebooks.  This information should be reviewed by 
personnel and any deviations from the norm should be addressed.  All records either in paper 
form, electronic, or a hybrid of both need to be archived safely in a location that can be 
accessible for review by both the company and any regulatory parties. 
McCulloch, Woodson, and Long (2014) point out that to maintain compliance with 21 
CFR Part 11, data within a hybrid system must be synchronized so that consistency exists 
between paper and electronic records.  Any data being maintained within an electronic format 
must have the “integrity of the record assured” (McCulloch, Woodson, and Long, 2014).  Data 
integrity issues within an electronic system can stem from both human error as well as 
intentional data manipulation.  In addition, while audit trails and other features such as built in 
time-stamps and electronic signatures can help, some type of data verification process needs to 
be employed after manual entry of critical data occurs.  These features can also point out if any 
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data had been entered outside of the expected work-flow or was not entered right after a testing 
procedure was complete.  A verification process can help to catch errors or raise red flags over 
potential data manipulation issues.  Different interfaces and systems used during various stages 
must be able to successfully migrate data as well as have specific verification plans that are 
adjusted for the needs of that system.    
II.A. 1.  Models 
Different models of validation have been discussed in pharmaceutical and FDA literature, 
specifically the V-model and the O-model (Stage, 2005).  The traditional V-model for validation 
has different documentation at each step and may not share documentation from one part of the 
process to the other.  Each step funnels down to the end result.  But once the procedure passes 
one step, there is no or little feedback given to a previous step with the documentation.  As a 
result, if there is a change made at one step due to new technology or regulatory demands, other 
areas and units may not be aware of this change. 
In the O-model there is more integration and sharing between the stages with the 
documentation.  The O-model allows for the newest versions of documentation and allows 
electronic records and signatures to move from one part of the process to the other.  So if 
changes in documentation and procedures take place at one step, the other units involved in other 
steps or procedures are notified so there is no disconnect between procedures or ignorance 
between steps (Stage, 2005). 
II.A.2. Security 
        According to Lopez (2003), the security requirements for electronic signatures must 
include privacy, authenticity, reliability, and non-repudiation.  Data encryption refers to the 
scrabbling of messages and the use of specific passwords or keys to generate the 
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output.  Authenticity, reliability and non-repudiation can be done through digital signatures, 
certificates, and hash algorithms.  Digital signatures are implemented through software to include 
the use of public and private keys as a way of verifying who modified or approved a 
record.  Hash algorithms condense messages and records into a fixed length so that the message 
cannot be easily recovered.  A system that has a reliable audit trail is essential to ensure 
authenticity of data and to show if there has been any tampering or who was involved in the 
process.  A reliable audit log should be able to show when each record was created, deleted, or 
tampered with and also the user associated with each of these changes.  If the audit log looks 
clean without any abnormalities or appearances of data manipulation, there can be some 
confidence behind the integrity of the data.  The electronic signatures and other features must be 
up to FDA standards as the FDA can request to look at the system during an audit or an 
inspection.  Being able to follow up on issues that come up during a consumer complaint or a 
recall of a product is also important.  Documentation for each of these features is an essential 
part of the electronic validation process.  An effective electronic validation system would have a 
way of organizing the documentation and also keeping track of the changes through audit trail 
and other system indicators (“System Validation for 21 CFR Compliance,” n.d.). 
II.A.3.  Validation Plans 
        The models followed by the companies along with system specifications help to ensure 
that the company is able to have a validation plan that will keep it in compliance.  According to 
Peters and Ferrence, “the Federal Food, Drug and Cosmetics Act Section 501 (a)(2)(B) which 
states that ‘a drug is deemed to be adulterated if the methods used in, or the facilities or controls 
used for, its manufacture, processing, packing, or holding do not conform to or were not operated 
or administered in conformity with Current Good Manufacturing Practices (CGMPs),’ serves as 
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the legal basis for the practice of validation” (2013).   Ferris (2000) discusses how various 
system requirements need to be looked at.  He describes a full life-cycle analysis starting from 
the different components used, the operating system in place to the applications installed while 
stressing the importance of documenting all the components.  When trying to implement new 
procedures or technology, an effective validation system can help to reduce time and costs while 
ensuring the integrity of the end product reaching the market. 
        The validation plan is based on the user requirements specifications (URS) which is 
determined by the company and the clients the company is serving.  This URS highlights the 
needs for the computer validation system that are essential for carrying out the goals and 
business processes for the organization.  In addition to the URS, there needs to be a project plan, 
functional and design specification, as well as user testing.  The project plan sets forth the 
timeline for the project.  Functional design specifies expected functionality while the design 
specifications explain how the system is expected to perform.  The needs of the company dictate 
how these features are set up and utilized.  In terms of testing new software and hardware, there 
is a three-level structure for user testing that should be followed: Installation Qualification (IQ); 
Operational Qualification (OQ); and Performance Qualification (PQ).  Additional important 
procedures for testing include Hardware Design Specifications (HDS), Software Design 
Specification (SDS), and Change Control (STSV Consulting, n.d.).  These procedures are always 
conducted and tested under the supervision of the Quality Assurance department.  
II.A.3.a. Installation Qualification (IQ) 
IQ occurs when a new product or instrument is installed for the first time.  The main 
objective of IQ is to ensure that the installation has been done as per the user’s requirement. 
Documentation includes the type of model, vendor that the model came from, and other data on 
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the origin of the product.  Any additional software or hardware needs for the product are also 
included within the documentation.  During this time, the product is assessed to look for any 
damages that may have occurred during transportation or perhaps during the installation process 
(“Installation Qualification and Operational Qualification”, n.d.).  For instance, IQ will test that 
the operating system has the appropriate processor, RAM, etc., that all files required to run the 
system are present, or that all documentation required to train system personnel has been 
approved (Ofni Systems, n.d.).  
II.A.3.b Operational Qualification (OQ) 
        Once the product is installed OQ takes place to ensure that the product is functioning as 
expected and that operations can continue.  Testing is done to make sure basic and expected 
functions work appropriately (“Installation Qualification and Operational Qualification”, 
n.d.).  Documentation on this process is necessary to ensure that testing was successful and also 
to ascertain that the expected outcomes should not be negatively affected.  Operational 
qualification is defined in the Functional Requirements Specification. Depending on the needs 
and the complexity of the system, OQ can be combined with IQ or Performance Qualification. 
For instance, OQ may test that each screen accepts appropriate data, that system security has 
been properly implemented, that all technological controls for compliance with 21 CFR Part 11 
are functioning as expected (Ofni Systems, n.d.) 
II.A.3.c. Performance Qualification (PQ) 
        PQ is a similar step to OQ in terms of testing but rather than just testing basic 
functionality, PQ tests how the product does when working with a heavy load (“What Are IQ, 
OQ, and PQ, and Why Are They Required,” n.d.).  The purpose of PQ is to make sure that the 
product can function during a realistic work environment.  Successful testing with a heavy load 
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indicates that the product will be able to perform during peak hours or may be also able to handle 
unexpected increases in activity.  PQ should be approved before protocol execution. For 
instance, PQ can determine if a system can handle multiple users without significant system lag 
or that a laboratory test correctly identifies a known material (Ofni Systems, n.d.) 
II.A.3.d. Hardware Design Specifications (HDS) 
          HDS identifies and delineates the control equipment requirements of the functional 
description and agreed control methods. HDS includes detailed equipment specifications like 
manufacturer, model number, serial number, and system configuration.  
II.A.3.e. Software Design Specification (SDS) 
          In the context of software, design specification includes a document that describes all data, 
architectural, interface and component level design for the software. While an HDS document 
will include information about a product and how it can be put together, SDS is designed to meet 
the unique needs of customers. 
II.A.3.f. Change Control  
         Change Control refers to how processes are managed to make changes within a controlled 
system. Change control demonstrates to regulatory authorities that validated systems remain 
under control during and after system changes. The following steps may be included in a change 
control project:  request a change, assess the impact of change, system development in a safe 
environment, system testing and re-validation, and implementation of the change (Ofni, n.d.) 
II.B. Compliance Failures 
When companies fail to effectively validate their electronic system, the FDA issues 
“tickets” for violation of FDA rules through Form 483.  McCulloch, Woodson, and Long (2014) 
point out that violations of 21 CFR Part 11 points towards data integrity issues and infractions on 
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current Good Manufacturing Practices (CGMP).  In 2008, the FDA found issues with data 
quality and banned 30 products from the market.  Companies faced massive fines with a few of 
them having to file for bankruptcy.  The FDA found Leiner Health Products to have issues with 
data manipulation and inadequate testing resulting in a $10 million fine.  In another instance, the 
Department of Justice issued a decree on behalf of the FDA on the Indian generic drug 
manufacturer Ranbaxy due to multiple violations (McCulloch, Woodson, and Long, 2014).  
These violations included incorrect testing procedures and inconsistent data records (“FDA AIP 
Letter to Ranbaxy Laboratories,” 2009).  Ranbaxy had to hire outside auditors and agree on 
making fundamental changes to their processes. Ranbaxy decommissioned one of its facilities in 
the United States due to the findings from the decree (McCulloch, Woodson, and Long, 2014).  
In their article, McCulloch, Woodson, and Long (2014) mention how the FDA decided to raise 
the enforcement profile on 21 CFR Part 11 in 2010 due to data integrity issues. The authors 
mention that within the last three years, the FDA has issued over thirty Warning Letters and 
Form 483 inspection observations. 
II.B.1. Which violations does 483 include? 
Form 483 is drafted after an inspection if the FDA inspector feels that any violations had 
taken place within a facility that is supposed to be under regulatory compliance.  FDA 
regulations are structured so that companies can take a broad regulation and apply it in a process 
that works for the particular business being conducted in a given facility.  However, the main 
aim of the regulations is to guide companies in making policies and procedures that will make 
the end products as safe as possible for the consumers.  The regulations require checks and 
balances throughout the development and production processes, as well as very thorough 
documentation and recordkeeping.  “When product is produced that does not meet its 
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specifications, the regulations require that the occurrence be investigated to determine why the 
product did not turn out as expected. Were all of the production procedures followed? Were all 
of the raw materials and/or components manufactured to their specifications? Did any conditions 
exist in the environment that could have contributed to the nonconformity? By answering the 
question of how the deviations happen, they can be prevented from recurring, and from 
nonconforming product potentially reaching customers” (MedMarc, n.d.).  According to 
Medmarc (n.d.), in 2013, the top five observations cited in medical device facilities were 
inadequate procedures for corrective and preventive actions (CAPAs); inadequate complaint 
handling procedures; inadequate documentation of CAPA activities; inadequate process 
validation; and inadequate Medical Device Reporting (MDR) procedures.  The three companies 
mentioned earlier were all guilty of one of these five violations.  Among their violations, Able 
Laboratories was guilty of inadequate process validation when the FDA found that their products 
did not meet established standards, specification and quality control criteria (“Able Laboratories 
Inspection Observations, 2005).  Ranbaxy was found to have inadequate MDR procedures since 
appropriate controls were not established over their computerized system.  Leiner Health 
Products’ data manipulation is an example of CAPA. 
Once a Form 483 has been issued, the company must make the decision to respond.  
However, the FDA only considers responses from the company within a fifteen-day period.  The 
company must show that it is taking steps to address the violations found within the Form 483 
that was produced after the inspection.  If the violations are relatively minor and if the company 
indicates within its response that it is taking the right steps to address the violations, then the 
FDA is likely to feel the matter resolved and close the case.  However, if there is no response or 
if the FDA feels that the response was inadequate, warning letters and further sanctions may 
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follow (MedMarc, n.d.).  In order to remedy a violation involving a recall, companies have to 
report back to the FDA district office within ten working days after the firm initiates any recall 
incase a risk was involved.  However, no report is required if there was no risk involved, but a 
record of recall is required to be maintained.  Actions taken by manufacturers to improve the 
performance or quality of a device includes market withdrawals, routine servicing, and stock 
recoveries (“Recalls, Corrections and Removals”, 2014). 
II.C. New Technology: A Virtualized, Cloud Environment 
In addition to maintaining data integrity, pharmaceutical companies must make sure that 
their electronic validation system can be effective in the event of changes and/or the introduction 
of new technology (Wingate, 2004).  A validation plan must be in place to allow records from 
old legacy systems to be checked.   Over the past few years, virtualization and cloud technology 
has started to become a more popular choice for businesses.  Virtualization is the software that 
manipulates hardware, while cloud computing refers to the service that results from this 
manipulation. So, in other words, virtualization is the basic element of cloud computing that 
helps deliver on the value of the cloud computing.   Mostly, the concepts of virtualization and 
cloud computing are confused because they work together to provide different types of services 
as in the private cloud.  For instance, the cloud can, and quite often includes virtualization 
products to deliver the compute service.  According to the vice president of compute solutions at 
IT firm, Weidenhammer, the difference between a true cloud and virtualization is that “a true 
cloud provides self-service capability, elasticity, automated management, scalability and pay-as 
you go service that is not inherent in virtualization” (Angeles, 2014). 
Bowers (2011) mentions how cloud technology is attractive to many organizations due to 
the ability to process, store, and access data through the cloud.  Companies may find this option 
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attractive if they are confident in the security being offered by the cloud.   The convenience of 
the cloud does have appeal for companies.  A cloud based infrastructure ensures that employees 
are securely accessing and exchanging the same data from the same location in the cloud while 
possibly being in different physical locations.  Additionally, cloud technology offers a low cost 
model since there are fewer maintenance needs and use of physical hardware is reduced 
(Sommer, 2013).  However, Sommer (2013) mentions that possibly only non-confidential data 
should be shared through the cloud.  The concern regarding non-confidential data would be 
important when using a public cloud but companies perhaps may be able to work on private 
clouds.  So what exactly is the difference between a private and public cloud? 
II.C.1. Private Cloud 
The main feature of private cloud that differentiates it from public cloud is that it is 
hosted on the company’s intranet.  All of the data is protected behind a firewall.  Private cloud is 
a great option for companies who already have expensive data centers because they can use their 
current infrastructure.  All management, maintenance and updating of data centers is the 
responsibility of the company.  Over the course of time, the servers will need to be replaced, 
which can get very expensive.  Despite these few drawbacks, private clouds offer an increased 
level of security and they share very few, if any, resources with other organizations (White, 
2016). 
II.C.2. Public Cloud 
As opposed to private cloud, the company is not at all responsible for maintaining and 
updating of the servers.  The data is stored in the provider’s data center and the provider is 
responsible for the management and maintenance of the data center.  The public cloud option is 
more attractive to most of the companies because it is time effective and also reduces lead times 
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in testing and deploying new products.  However, the quality of data security is not as strong 
compared to that of the private cloud environment.  Experts, however, explain that even though 
companies do not control the security of a public cloud, all of their data remains separate from 
others and security breaches of public clouds are rare (White, 2016) 
While an attractive option financially, the pharmaceutical industry has to figure out if 
cloud-based technology can be FDA compliant.  According to Williams’ presentation, 
“Regulated Applications in the Cloud: Aspects of Security and Validation” (2011), prior to 
running regulated applications in the cloud, pharmaceutical companies need to figure out ways to 
assess and mitigate the security risks involving moving to a virtual environment.  Some of these 
risks address data security such as encryption and VPN.  Pharmaceutical companies connecting 
to cloud service providers need to make sure that they have secure and encrypted IPsec VPN 
connection.  Traffic traveling between the two networks is encrypted by one VPN gateway, then 
decrypted by the other VPN gateway.  This process protects the data as it travels over the 
insecure internet.  For instance, a pharmaceutical company may desire its employees to be able 
to work remotely from their homes and while traveling.  However, this may pose concerns like 
exposing its intranet to unauthorized access and the possibility that security of sensitive 
information may be compromised (Microsoft, 2015).  Additionally, outside vendors who own 
and support the software for cloud technology may not have an understanding of pharmaceutical 
security and regulatory requirements.  Sommer (2013) points out that companies do not have 
much control over changes to and maintenance of their software.  The companies have to wait 
for the vendor to come up with updates and patches to address concerns.  These issues may 
possibly lead to service access issues which may be a major problem on the customer end.  The 
physical server location may cause issues since 21 CFR Part 11 dictates that computer systems 
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must be available for FDA inspection.  Since the physical servers would be maintained by the 
outside vendor, if they are not available for FDA inspection, there would be a definite violation 
of 21 CFR Part 11.  These concerns hold true if the company was looking to utilize an outside 
vendor and a public cloud.  However, some of these concerns may be mitigated if a company 
decides to go to a private cloud and are able to stay in compliance with FDA regulations. 
According to Williams (2011), these issues and concerns regarding cloud technology 
need to be addressed through qualification and validation.  An approach has to be taken to figure 
out what needs and procedures would address these issues.  Similar to the rest of the validation 
process, documentation needs to be created and maintained to prove compliance with regulatory 
concerns.  To address data security, best practices dictate that the company should look at Virtual 
Machine (VM) level security; multi-layered defense; patch management; and data protection and 
encryption.  
VM refers to a logical process that interfaces with emulated hardware and is managed by 
an underlying control program.  Applications need to be updated and the infrastructure on which 
the application is to run should be qualified.  Documentation for each of these parts will be 
needed for the overall validation plan.  Multi-layered defense or multi-level security (MLS) 
refers to the application of a computer system to process information with incompatible 
classifications, permit access to users with different security clearances and prevent users from 
obtaining access to information for which they lack authorization.  Patch management is an area 
of systems management that involves acquiring, testing, and installing multiple patches to a 
computer system.  Patch management tasks include: maintaining current knowledge of available 
patches, deciding what patches are appropriate for particular systems, ensuring that patches are 
installed properly, testing systems after installation, and documenting all associated procedures.  
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An advantage of applying patches in VM environment is that snapshots can be acquired prior to 
the application any new security patches.  In case, an issue arises after deploying patches the 
operating system can be rolled back to the previous stage.  
III. Case Study: Encompass Elements, Inc. 
            According to its public website, Encompass Elements, Inc is a company that provides 
“support across the categories of integrated direct marketing, fulfillment and distribution, digital 
technology, and strategy and planning” (n.d.).  Working with pharmaceutical companies as some 
of their clientele, Encompass Elements needs to make sure that they adhere to regulations set 
forth by the FDA (Encompass Elements, n.d.). They also make it a point to keep in place an 
electronic validation system that works and meets client needs and expectations.  Specifically, 
the company handles procurement and fulfillment for its clients through the development 
warehouse management and shipping application.  In terms of size, Encompass Elements is a 
smaller company with a staff of about 200 employees (anonymous employee, personal 
communication, November 3, 2015).  Through an interview process, a few of their employees 
discussed their views of the company’s current electronic validation system.  These employees 
have a different range of responsibilities in the company but all of them are aware of the 
electronic validation system and are able to comment on how the system operates. 
III.A. Strengths 
        The employees interviewed generally seemed to have a favorable view of the electronic 
validation system.  One employee (personal communication, November 2, 2015) believes that 
the SOPs for the validation of the controlled environment is critical for the company and well 
handled.  Specific procedures that are performed and documented well include IQ, OQ, and 
change control.  The Director of Quality Control (QA) (anonymous employee, personal 
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communication, November 5, 2015) believes that a high level of expertise exists among the staff 
involved with validation (anonymous employee, personal communication, November 5, 
2015).  Additionally, the staff has great familiarity with FDA requirements and the need for 
documentation.  The Quality Control department and the validation team are considered 
strengths of the company with regard to the electronic validation system.  One of the employees 
(2015) mentioned that the director of the QA department has an open door policy to allow any 
individuals to stop by with concerns.  Additionally, quarterly trainings are held for updates on 
good manufacturing practices (GMP) and the validation system. The QA department gets 
updates from the FDA as well as the Product Development Management Association (PDMA) 
which provide information on issues and concerns that the QA department would need to share 
with the rest of the company (anonymous employee, 2015). 
        With a strong validation team and QA department, Encompass Elements employees have 
a zero tolerance policy with regard to following regulations.  Employees who work within the 
regulatory environment must be aware of what needs to be done and what processes need to be 
followed including producing and maintaining documentation (anonymous employee, 
2015).  Additionally, the QA department has set up a “STOP” mail box (anonymous employee, 
2015).  If any employee notices any issues and needs to report an incident, they email a 
description of the issue to the mail box.  The emails are reviewed by the QA department, which 
determines what the next steps are, who needs to get involved, and what should be done to 
ensure there is no violation of regulations. 
        To ensure that software and hardware are well maintained and FDA-compliant, 
Encompass Elements has a strong technology staff from the developers to the database and 
network teams (anonymous employee, 2015).  The in-house developers are able to develop and 
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customize code in order to make changes for maintenance or to remediate issues during or after 
the validation process (anonymous employee, personal communication. November 4, 
2015).  The technology staff understands that there are technological updates and continues to 
seek more training as well as qualification to ensure that the company can keep up with any 
changes.             
III.B. Balancing System Requirements and Expectations for Production 
One employee (2015) mentions that the system works and runs as expected without much 
need for downtime.  The steps put in place through the validation process reduce unexpected 
surprises which is critical for day-to-day operations and client relations.  Additionally, the client 
base expects that the company is up-to-date and aware of regulatory changes and concerns.  New 
regulations or updates from the FDA do not excuse any type of delays to meet production 
expectations.  The company has to make financial choices to ensure compliance concerns and 
client expectations are met (anonymous employee, 2015). 
Upper management within Encompass Elements fully supports both the validation 
process as well as the maintenance of current technology standards (anonymous employee, 
2015).  Superiors fully understand the risks involved in the event of the company falling out of 
compliance, and they also realize that the utilization of technology is essential to improve 
performance and meet market demands.  Upper management encourages the development of 
internal applications that can be maintained and adjusted to meet regulations (anonymous 
employee, 2015).  Additionally, with the need for compliance, concerns with traceability and 
having systems with good audit trails is considered of high importance (anonymous employee, 
2015). 
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III.C. Weaknesses 
 While the company’s QA department is strong and is very concerned about being on top 
of regulations, one of the employees mentioned (2015) that the director of the department is still 
not satisfied with where the validation system is and believes that there is still room for 
improvement.  Specifically, the director of QA believes that there could be more comprehensive 
testing with more thorough reviews of access levels.  These two features are considered among 
the threats to processes supported by the validation system.  The employee also pointed out a few 
specific processes that need improvement due to limited resources.  These process include pick 
and pack processes and inventory classifications.  Limited technology leaves the pick and pack 
process in a hybrid form.  This particular employee would like to see this process moved to being 
completely paperless.  If classification of inventory was done better, there would be faster 
processing because capturing the product in the right area would be done more efficiently.   
 Outside of the QA department, employees (2015) believe an additional challenge with the 
current validation process includes the fact that the change control and testing processes can slow 
implementation of new functionality and hardware.  On one end, QA believes there should be 
more testing but there need to be changes to ensure that the testing is more efficient and that 
there is no delay getting the end product to the clients.  QA would need to have conversations 
with the employees who are working with the clients to get an understanding of the type of 
deadlines that exist to ensure that if any testing procedures are taking place they can all be done 
within a reasonable timeframe. 
Based on the response earlier that Encompass Elements only has about 200 employees 
making it a smaller company that does not have unlimited financial and personal resources.  The 
limitation of resources may prove to be a threat for the company down the road.  These legacy 
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systems pose a threat in terms of proper validation (anonymous employee, 2015).  Another 
employee (2015) believes specifically that some of the physical servers are getting obsolete as 
well and that there is need for upgrades and further research for these servers.  There are 
performance concerns with these servers that would have a negative effect on company 
processes.  A possible solution could be to move the servers to a VMware platform and have the 
servers in a remote connection.  One employee (2015) points out that location connectivity is a 
threat that the company has to address.  If these servers crash or something else happens that 
requires significant maintenance downtime, customers will be highly inconvenienced and may 
negatively impact customer retention. 
III.D. New Technology 
 While many of the weaknesses of the organization seem to point to a need for more 
investment in technology, upper management of the organization understands the need to stay 
ahead of technology but is also concerned about the costs and resources needed (McCool, 
2015).  Additionally, state of the art technology is recognized by key decision makers. Standards 
to perform at this specific level of technology is recognized and the company works to maintain 
its ability to operate at this level until a reassessment determines a need for a change or an 
upgrade (anonymous employee, 2015).  This current state of technology includes consideration 
of a virtual environment.  The company is currently running 90 percent of its servers on VMware 
virtual environment (anonymous employee, 2015).  The physical servers have to remain due to 
FDA compliance including 21 CFR Part 11 because the FDA has to be able to inspect the 
electronic systems during an audit or inspection.  Once the company determines a way to stay in 
compliance, Encompass Elements will likely move to a completely virtualized environment.   
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 If costs have to be reduced and processes have to be improved, staying ahead of trends 
and determining ways to continue delivering high quality products are essential.  Overall, the 
respondents interviewed seemed to believe that the company did a good job for some of their 
processes and is adapting to new technology.  Due to its smaller size and infrequence FDA and 
client audits, Encompass Elements is incented to stay within regulatory compliance as well as 
ways to improve processes.  One of the employees (2015) points out that the company tries to 
maintain appropriate technology levels and stay a step ahead of current demands.  This practice 
explains why Encompass Elements is considering ways to go to a completely virtualized 
environment to improve processes and save on costs.  However, based on current client needs 
and the technology available at this time, there is no immediate threat to the company if it does 
not move to a completely virtualized environment (anonymous employee, 2015).  As long as the 
company is aware of its current technological capabilities and is keeping abreast with new 
technological development, it is on the right track.  While technology is being embraced by the 
company, the adaptation of technology has to be balanced between regulatory issues, client 
needs and expectations, and financial as well as human capital resources. 
IV. Conclusion 
        The original hypothesis of this project started with the assumption that companies still 
struggle to design and follow effective validation plans that can adapt to changes in technology 
and regulatory demands.  The literature on the development of electronic validation indicates that 
there was some initial confusion about how to utilize technology when 21 CFR Part 11 was first 
introduced.  Since electronic validation was not something that was regularly followed initially, a 
disconnect existed between FDA expectations and the industry’s capabilities and technology 
infrastructure.  Some companies such as Able Laboratories, Leiner Health Products, and 
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Ranbaxy ran into major compliance issues that greatly damaged their businesses.  Companies 
must ensure that they are following the guidelines set forth by 21 CFR Part 11 because the FDA 
is still using this guideline as one of the key pieces for audits and is issuing warning letters based 
on non-compliance of this regulation.   
The case study on Encompass Elements shows a company that is very aware of 
compliance issues as well as its own limitations while maintaining a good validation 
system.  Three specific themes can be pulled from the case study that can help drive compliance 
and the maintenance of electronic validation: embracing technology, ensuring high-level quality 
assurance, and aligning with business strategies. 
Embracing Technology 
 Encompass Elements through the organizational ranks has embraced technology and 
wants to stay ahead of technological changes.  Encompass Elements is looking towards moving 
to a completely virtualized environment.  Additionally, those interviewed mentioned weaknesses 
that need to be addressed such as old servers or certain processes that need to be 
modernized.  The strength of the technical team and in-house programmers who continue to look 
for more certification and training highlights how technology plays a key role for companies 
within the industry.  The awareness of technology limitations and mindfulness about what 
technological trends need to be adopted help to keep the company on track in terms of complying 
with regulations, maintaining data integrity, and producing a high quality end 
product.  Additionally, the understanding of the need for good documentation on the technical 
side can help with any moves or adaptation to new technology.    
High Level Quality Assurance (QA) 
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 Based on the feedback from the employees interviewed at Encompass Elements, the 
strength and competence of their QA department was evident.  The responses from those 
interviewed seemed to indicate that the QA department is considered an important part of the 
overall organizational structure.  With the zero tolerance policy, the QA department is 
empowered by the organization to educate those involved within the regulatory environment.  
Encompass Elements show that when a strong QA department exists that really helps to keep a 
company compliant and able to meet regulatory demands.   
 Alignment with Business Strategy 
 Encompass Elements is an example where electronic system validation is recognized as 
being an essential part of the business culture or the company.  Upper management is aware how 
not being able to meet regulatory requirements can prove to be detrimental to and a liability 
concern for the organization.  They strongly support traceability and systems with reliable audit 
trails.  The strength of the QA department within the organizational structure also indicates how 
meeting regulatory demands is considered an essential part of the company’s business strategy.  
Additionally, the company recognizes the importance of technology.  By agreeing on a certain 
technology standard, the company understands the level of commitment that is needed to 
maintain systems.  While those who were interviewed did mention possible improvements with 
additional technological resources, financial limitations may be part of the reason why these 
issues are not yet fully resolved.  The alignment with business strategy makes sure that the 
commitment to technology and validation is kept in mind when discussing the use of resources.   
Future Research  
Contrary to the original hypothesis that many companies struggle with electronic validation, 
Encompass Elements appears to be a company that has a sufficient electronic validation system 
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and support for utilizing new technology.  Encompass Elements is fully aware of its current 
limitations but also has an understanding of regulations, the need for validation, and the 
importance of looking towards technological changes.  Future research with other companies is 
needed to see if they are similar to Encompass Elements or if they do struggle to figure out how 
to meet regulatory demands and technological changes.  It would be interesting to see how the 
three themes of embracing technology, high level QA, and the alignment of business strategy 
affect electronic system validation for other companies.  With emphasis on the importance of 
regulations such as 21 CFR Part 11 and the introduction of technological changes (such as cloud 
technology), pharmaceutical companies will have to create a balance between addressing these 
concerns, their financial resources, and consumer expectations to remain competitive within the 
industry. 
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